



CLINICAL GUIDELINE

Asthma

Preferred list inhaler device guide (Primary and Secondary care)

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Original Date of Approval:	1 st February 2016
Date of Update:	22 nd November 2017
Review Date:	23 rd November 2020
Lead Author:	Janey Lennon
Approval Group:	Medicines Utilisation Subcommittee of ADTC
Clinical Content Changes (Y/N):	Yes
Version no:	2

Adult Asthma (18 years and over) - Preferred list Inhaler Device Guide (primary and secondary care)

Please see NHSGG&C Asthma Guideline for full therapeutic guideline and NHSGGC formulary



Asthma Management	Prescribing Choice			No of doses/ inhaler	Cost per 200 puffs	
SABA	1st Preferred list	Salbutamol CFC free inhaler	Aerosol (MDI)	100 micrograms, two puffs when required	200	£1.50
	2nd Preferred list	Salbutamol Easyhaler®	Dry powder inhaler	100 micrograms, two puffs when required	200	£3.31

Cost over 30 days						
Regular preventer therapy- ICS (low dose*)	1st Preferred list	Clenil Modulite®	Aerosol (MDI)	100 micrograms, two puffs twice daily	200	£4.45
	2nd Preferred list	Beclometasone Easyhaler®	Dry powder inhaler	200 micrograms, one puff twice daily	200	£4.48

Cost over 30 days						
Initial add on therapy - combined ICS (low dose*) and LABA	Preferred list	Fostair® 100/6	Aerosol (MDI)	one puff twice daily	120	£14.66
	Preferred list	Fostair® 100/6 Nexthaler®	Dry powder inhaler	one puff twice daily	120	£14.66

Cost over 30 days						
Additional add-on therapies (medium dose ICS and LABA*) see GGC guideline for other options	1st Preferred list	Fostair® 100/6	Aerosol (MDI)	two puffs twice daily	120	£29.32
	1st Preferred list	Fostair® 100/6 Nexthaler®	Dry powder inhaler	two puffs twice daily	120	£29.32
	2nd Preferred list	Relvar® 92/22 Ellipta	Dry powder inhaler	one puff once a day	30	£22.00

Spiriva Respimat is the total formulary choice LAMA for asthma- can be considered (as an addition to ICS/LABA) for patients on medium or high dose ICS and LABA with poorly controlled asthma, see NHSGGC formulary for details

Cost over 30 days						
High dose therapies (high dose ICS and LABA*)	1st Preferred list	Fostair® 200/6	Aerosol (MDI)	two puffs twice daily	120	£29.32
	1st Preferred list	Fostair® 200/6 Nexthaler	Dry powder inhaler	two puffs twice daily	120	£29.32
	2nd Preferred list	Relvar® 184/22 Ellipta	Dry powder inhaler	one puff once a day	30	£29.50

*Refer to BTS/SIGN or NHSGGC asthma guideline for table of ICS categorisation by dose

Abbreviations:

SABA: short-acting beta₂ agonist
 MDI: metered dose inhaler
 ICS: inhaled corticosteroid
 LABA: long-acting beta₂ agonist
 LAMA: long-acting muscarinic antagonist
 DPI: dry powder inhaler

Clenil®= beclometasone dipropionate
 Fostair® = extra-fine particle size beclometasone/formoterol
 Relvar® = fluticasone furoate/vilanterol
 Spiriva Respimat® = tiotropium fine mist inhaler
 (Costs from BNF Sept 2017)

NHSGG&C Prescribing Support Disclaimer
 Valid at the time of Preparation 06/10/2017
 Date Ratified (MU) 22/10/2017
 Renewal Date 22/10/2020
 Authors: South Sector Respiratory Prescribing Support Team

For dose equivalencies and other prescribing/ licensing information please see individual BNF/SPC for guidance